Literature DB >> 11529259

COPD: management of acute exacerbations and chronic stable disease.

M H Hunter1, D E King.   

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (COPD) are treated with oxygen (in hypoxemic patients), inhaled beta2 agonists, inhaled anticholinergics, antibiotics and systemic corticosteroids. Methylxanthine therapy may be considered in patients who do not respond to other bronchodilators. Antibiotic therapy is directed at the most common pathogens, including Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Mild to moderate exacerbations of COPD are usually treated with older broad-spectrum antibiotics such as doxycycline, trimethoprim-sulfamethoxazole and amoxicillin-clavulanate potassium. Treatment with augmented penicillins, fluoroquinolones, third-generation cephalosporins or aminoglycosides may be considered in patients with more severe exacerbations. The management of chronic stable COPD always includes smoking cessation and oxygen therapy. Inhaled beta2 agonists, inhaled anticholinergics and systemic corticosteroids provide short-term benefits in patients with chronic stable disease. Inhaled corticosteroids decrease airway reactivity and reduce the use of health care services for management of respiratory symptoms. Preventing acute exacerbations helps to reduce long-term complications. Long-term oxygen therapy, regular monitoring of pulmonary function and referral for pulmonary rehabilitation are often indicated. Influenza and pneumococcal vaccines should be given. Patients who do not respond to standard therapies may benefit from surgery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529259

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  9 in total

1.  Evaluation of stat orders in a teaching hospital: a chart review.

Authors:  Fanak Fahimi; Zahra Sahraee; Shahideh Amini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Physical therapy practice patterns in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Leslie Harth; Jennifer Stuart; Catherine Montgomery; Karol Pintier; Susan Czyzo; Kylie Hill; Roger Goldstein; Dina Brooks
Journal:  Can Respir J       Date:  2009 May-Jun       Impact factor: 2.409

3.  A systematic review and meta-analysis of herbal medicine on chronic obstructive pulmonary diseases.

Authors:  Hai Yong Chen; Chun Ho Ma; Ke-Jian Cao; James Chung-Man Ho; Eric Ziea; Vivian Taam Wong; Zhang-Jin Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-26       Impact factor: 2.629

4.  Study of drug utilization pattern for acute exacerbation of chronic obstructive pulmonary disease in patients attending a government hospital in kerala, India.

Authors:  Sajesh Kalkandi Veettil; Kingston Rajiah; Suresh Kumar
Journal:  J Family Med Prim Care       Date:  2014-07

5.  Moraxella catarrhalis uses a twin-arginine translocation system to secrete the β-lactamase BRO-2.

Authors:  Rachel Balder; Teresa L Shaffer; Eric R Lafontaine
Journal:  BMC Microbiol       Date:  2013-06-19       Impact factor: 3.605

6.  Use of the Chinchilla model to evaluate the vaccinogenic potential of the Moraxella catarrhalis filamentous hemagglutinin-like proteins MhaB1 and MhaB2.

Authors:  Teresa L Shaffer; Rachel Balder; Sean W Buskirk; Robert J Hogan; Eric R Lafontaine
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

Review 7.  Treatment of mild chronic obstructive pulmonary disease.

Authors:  Alex Chee; Don D Sin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

8.  Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location.

Authors:  Lauren Becnel Boyd; Robert L Atmar; Graham L Randall; Richard J Hamill; David Steffen; Lynn Zechiedrich
Journal:  BMC Infect Dis       Date:  2008-01-15       Impact factor: 3.090

9.  Prevalence and resistance pattern of Moraxella catarrhalis in community-acquired lower respiratory tract infections.

Authors:  Safia Bader Uddin Shaikh; Zafar Ahmed; Syed Ali Arsalan; Sana Shafiq
Journal:  Infect Drug Resist       Date:  2015-07-31       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.